ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Sold by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC decreased its stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 43.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 83,240 shares of the biotechnology company's stock after selling 65,250 shares during the quarter. Los Angeles Capital Management LLC's holdings in ADMA Biologics were worth $1,428,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Hollencrest Capital Management bought a new stake in shares of ADMA Biologics during the third quarter valued at approximately $30,000. Larson Financial Group LLC bought a new stake in ADMA Biologics during the 3rd quarter valued at $31,000. GAMMA Investing LLC lifted its holdings in shares of ADMA Biologics by 106.6% in the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company's stock worth $32,000 after buying an additional 967 shares during the period. National Bank of Canada FI bought a new position in shares of ADMA Biologics during the 3rd quarter worth $35,000. Finally, Harvest Fund Management Co. Ltd purchased a new position in shares of ADMA Biologics during the third quarter valued at $62,000. 75.68% of the stock is owned by hedge funds and other institutional investors.

ADMA Biologics Stock Up 2.8 %

ADMA Biologics stock traded up $0.45 during midday trading on Tuesday, reaching $16.28. The company's stock had a trading volume of 3,835,382 shares, compared to its average volume of 3,341,864. ADMA Biologics, Inc. has a 52-week low of $5.52 and a 52-week high of $23.64. The stock has a market capitalization of $3.85 billion, a P/E ratio of 58.25 and a beta of 0.75. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The stock's 50-day simple moving average is $16.69 and its 200-day simple moving average is $17.98.

Remove Ads

Wall Street Analyst Weigh In

Several brokerages have issued reports on ADMA. HC Wainwright increased their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a "buy" rating in a report on Friday, November 8th. Cantor Fitzgerald reiterated an "overweight" rating and set a $25.00 price objective on shares of ADMA Biologics in a research note on Tuesday. Finally, Raymond James boosted their price objective on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a research note on Friday, November 8th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.